The Asia Pacific ENT device market saw a severe short-term impact from the COVID-19 pandemic in 2020 as many ENT procedures were delayed or canceled. Although the market rebounded in 2021 and 2022, owing to the recovery of deferred procedures, the pace of market growth was hindered by competition from nonsurgical alternative treatments, such as antibiotics. However, as the COVID-19 situation stabilizes, there will be increasing adoption of innovative and premium-priced products, such as flexiblescopes, RF handpieces, and powered instruments; as a result, the Asia Pacific market for ENT devices will grow at a modest pace following the impact of the pandemic.
This Medtech 360 Report provides high-level market metrics for ENT devices in the Asia Pacific region, including country-level data for major countries and aggregate data for the rest of the Asia Pacific from 2019 through 2031.